• LAST PRICE
    0.4728
  • TODAY'S CHANGE (%)
    Trending Down-0.0272 (-5.4400%)
  • Bid / Lots
    0.4725/ 15
  • Ask / Lots
    0.5000/ 20
  • Open / Previous Close
    0.4762 / 0.5000
  • Day Range
    Low 0.4712
    High 0.4850
  • 52 Week Range
    Low 0.4300
    High 2.6800
  • Volume
    4,611
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.5
TimeVolumeSLRX
09:32 ET3940.4762
09:43 ET20000.4713
10:08 ET1000.4714
11:04 ET10000.485
11:49 ET2160.4725
12:32 ET1000.473
02:49 ET2000.4728
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLRX
Salarius Pharmaceuticals Inc
2.2M
-0.1x
---
United StatesQLGN
Qualigen Therapeutics Inc
2.1M
-0.1x
---
United StatesSCNI
Scinai Immunotherapeutics Ltd
2.1M
-0.1x
---
United StatesBPTH
Bio Path Holdings Inc
2.3M
-0.1x
---
United StatesCWBR
CohBar Inc
2.3M
-0.2x
---
United StatesATNF
180 Life Sciences Corp
1.8M
0.0x
---
As of 2024-04-15

Company Information

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.

Contact Information

Headquarters
2450 Holcombe Blvd Ste J-608HOUSTON, TX, United States 77021-2041
Phone
617-874-1821
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
William McVicar
President, Chief Executive Officer, Director
David Arthur
Chief Financial Officer, Executive Vice President - Finance
Mark Rosenblum
Lead Independent Director
Paul Lammers
Independent Director
Tess Burleson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.2M
Revenue (TTM)
$0.00
Shares Outstanding
4.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.96
EPS
$-4.54
Book Value
$1.34
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.